Skip to main content

Are you Dr. Nicholls?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 48 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Stephen Nicholls, MD is a vascular surgeon in Vancouver, Washington. He is currently licensed to practice medicine in Washington, Wisconsin, and Pennsylvania.

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Vascular Surgery, 1985 - 1986
  • University of Washington
    University of WashingtonResidency, Surgery, 1983 - 1985
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Surgery, 1979 - 1983
  • Montefiore Medical Center/Albert Einstein College of Medicine
    Montefiore Medical Center/Albert Einstein College of MedicineResidency, Surgery, 1976 - 1977
  • University of Auckland Faculty of Medicine and Health Sciences
    University of Auckland Faculty of Medicine and Health SciencesClass of 1974

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1979 - 2021
  • WI State Medical License
    WI State Medical License 2019 - 2021
  • WA State Medical License
    WA State Medical License 1986 - 2020
  • NY State Medical License
    NY State Medical License 1978 - 2020

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons
  • Fellow (FACC) American College of Cardiology
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?
    Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?August 15th, 2022
  • NewAmsterdam Pharma Announces ROSE Phase 2 Trial Results Accepted for Featured Science Presentation at 2021 AHA Scientific Sessions
    NewAmsterdam Pharma Announces ROSE Phase 2 Trial Results Accepted for Featured Science Presentation at 2021 AHA Scientific SessionsNovember 8th, 2021
  • New Data at ESC Congress 2021 Shows Repatha® (Evolocumab) Improves Features of Plaque Stability in Patients with Acute Coronary Syndrome (ACS)
    New Data at ESC Congress 2021 Shows Repatha® (Evolocumab) Improves Features of Plaque Stability in Patients with Acute Coronary Syndrome (ACS)August 27th, 2021
  • Join now to see all

Professional Memberships